Cargando…
Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming
Rewiring cellular sensors to trigger non-natural responses is fundamental for therapeutic cell engineering. Current designs rely on engineered receptors that are limited to single inputs, and often suffer from high leakiness and low fold induction. Here, we present Generalized Engineered Activation...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992713/ https://www.ncbi.nlm.nih.gov/pubmed/32001704 http://dx.doi.org/10.1038/s41467-020-14397-8 |
_version_ | 1783492889409486848 |
---|---|
author | Krawczyk, Krzysztof Scheller, Leo Kim, Hyojin Fussenegger, Martin |
author_facet | Krawczyk, Krzysztof Scheller, Leo Kim, Hyojin Fussenegger, Martin |
author_sort | Krawczyk, Krzysztof |
collection | PubMed |
description | Rewiring cellular sensors to trigger non-natural responses is fundamental for therapeutic cell engineering. Current designs rely on engineered receptors that are limited to single inputs, and often suffer from high leakiness and low fold induction. Here, we present Generalized Engineered Activation Regulators (GEARs) that overcome these limitations by being pathway-specific rather than input-specific. GEARs consist of the MS2 bacteriophage coat protein fused to regulatory or transactivation domains, and work by rerouting activation of the NFAT, NFκB, MAPK or SMAD pathways to dCas9-directed gene expression from genomic loci. This system enables membrane depolarization-induced activation of insulin expression in β-mimetic cells and IL-12 expression in activated Jurkat cells, as well as IL-12 production in response to the immunomodulatory cytokines TGFβ and TNFα in HEK293T cells. Engineered cells with the ability to reinterpret the extracellular milieu have potential for applications in immunotherapy and in the treatment of metabolic diseases. |
format | Online Article Text |
id | pubmed-6992713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69927132020-02-03 Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming Krawczyk, Krzysztof Scheller, Leo Kim, Hyojin Fussenegger, Martin Nat Commun Article Rewiring cellular sensors to trigger non-natural responses is fundamental for therapeutic cell engineering. Current designs rely on engineered receptors that are limited to single inputs, and often suffer from high leakiness and low fold induction. Here, we present Generalized Engineered Activation Regulators (GEARs) that overcome these limitations by being pathway-specific rather than input-specific. GEARs consist of the MS2 bacteriophage coat protein fused to regulatory or transactivation domains, and work by rerouting activation of the NFAT, NFκB, MAPK or SMAD pathways to dCas9-directed gene expression from genomic loci. This system enables membrane depolarization-induced activation of insulin expression in β-mimetic cells and IL-12 expression in activated Jurkat cells, as well as IL-12 production in response to the immunomodulatory cytokines TGFβ and TNFα in HEK293T cells. Engineered cells with the ability to reinterpret the extracellular milieu have potential for applications in immunotherapy and in the treatment of metabolic diseases. Nature Publishing Group UK 2020-01-30 /pmc/articles/PMC6992713/ /pubmed/32001704 http://dx.doi.org/10.1038/s41467-020-14397-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Krawczyk, Krzysztof Scheller, Leo Kim, Hyojin Fussenegger, Martin Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title | Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title_full | Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title_fullStr | Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title_full_unstemmed | Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title_short | Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
title_sort | rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992713/ https://www.ncbi.nlm.nih.gov/pubmed/32001704 http://dx.doi.org/10.1038/s41467-020-14397-8 |
work_keys_str_mv | AT krawczykkrzysztof rewiringofendogenoussignalingpathwaystogenomictargetsfortherapeuticcellreprogramming AT schellerleo rewiringofendogenoussignalingpathwaystogenomictargetsfortherapeuticcellreprogramming AT kimhyojin rewiringofendogenoussignalingpathwaystogenomictargetsfortherapeuticcellreprogramming AT fusseneggermartin rewiringofendogenoussignalingpathwaystogenomictargetsfortherapeuticcellreprogramming |